Biocryst Pharmaceuticals Inc BCRX
The biggest changes in the 10-K filed Feb 26, 2026, in management's words
10-K, Item 7This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.
Operating margin
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
“$1.2 million decrease in research and development expenses associated with our European ORLADEYO business (excluding stock-based compensation) due to the sale of our European ORLADEYO business to Neopharmed on October 1, 2025.”
Read it in the 10-K
Revenue
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
“$244.0 million increase in license revenue primarily comprised of $243.3 million related to the license of intellectual property to Neopharmed;”
Read it in the 10-K
“$168.7 million increase in ORLADEYO revenue, excluding revenues associated with our European ORLADEYO business, primarily due to an increase in volume of direct sales of ORLADEYO, which was driven by strong patient demand, an increase in price, and an increase in the rate of paid shipments; and”
Read it in the 10-K
What management said, year by year
The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)
Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.
Revenue
2 of 2 years explained-
FY 2025 +94.1%
“$244.0 million increase in license revenue primarily comprised of $243.3 million related to the license of intellectual property to Neopharmed;”
Read it in the FY 2025 10-K“$168.7 million increase in ORLADEYO revenue, excluding revenues associated with our European ORLADEYO business, primarily due to an increase in volume of direct sales of ORLADEYO, which was driven by strong patient demand, an increase in price, and an increase in the rate of paid shipments; and”
Read it in the FY 2025 10-K -
FY 2024 +36.0%
“The increase in total revenues was due to a $111.7 million increase in ORLADEYO net revenue, including royalties, primarily due to an increase in direct sales of ORLADEYO due to both an increase in volume, driven by strong patient demand, and an increase in price.”
Read it in the FY 2024 10-K“The increase in total revenues was also due to an increase in other revenues of $7.6 million, primarily due to an increase in direct sales of RAPIVAB.”
Read it in the FY 2024 10-K
Operating margin
2 of 2 years explained-
FY 2025 +39.5 pts
“$1.2 million decrease in research and development expenses associated with our European ORLADEYO business (excluding stock-based compensation) due to the sale of our European ORLADEYO business to Neopharmed on October 1, 2025.”
Read it in the FY 2025 10-K -
FY 2024 +30.7 pts
“Research and development expenses decreased to $174.6 million for the year ended December 31, 2024 from $216.6 million for the year ended December 31, 2023, primarily due to decreased expenses driven by the discontinuation and close-out of the Factor D programs, BCX10013 and BCX9930.”
Read it in the FY 2024 10-K
Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K
Sources
The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.
Also
Financials: the numbers year by year.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BCRX/export.csv") into a cell.